Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas

Y. H. Kim; H. S. Lee; H. J. Lee; K. Hur; W. H. Kim; Y. J. Bang; S. J. Kim; K. U. Lee; K. J. Choe; H. K. Yang

doi:10.1093/annonc/mdh131

Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas

Y. H. Kim, H. S. Lee, H. J. Lee, K. Hur, W. H. Kim, Y. J. Bang, S. J. Kim, K. U. Lee, K. J. Choe, H. K. Yang

Department of Medicine

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

Background: Transforming growth factor-β (TGF-β) modulates the growth and function of many cells, including those with malignant transformation. Smad proteins have been identified as major components in the intracellular signaling of TGF-β family members. Patients and methods: To clarify the correlations between clinicopathologic profiles and the patient's survival, the expression of common mediator Smad (Smad4) and inhibitory Smad (Smad7) were evaluated immunohistochemically in 304 consecutive gastric carcinomas using the tissue array method. Results: Positive Smad4 expression was observed in 266 (87.5%) tumors and positive Smad7 expression in 98 (32.2%) tumors. The prognosis of patients with a Smad4-positive tumor was significantly better than that of the patients with a negative tumor. The survival rate was significantly higher in patients with negative Smad7 expression than those with positive Smad7 expression. In subgroup analysis according to TNM (tumour-node-metastasis) stage, both Smad4 and Smad7 showed most significant prognostic differences in stage I gastric cancer patients. Multivariate analysis indicated that tumor size, depth of invasion, lymph node metastasis and Smad7 expression were independent prognostic factors. Conclusion: Enhanced expression of the TGF-β signaling inhibitor Smad7 may present one of the novel mechanisms of TGF-β resistance in human gastric carcinomas.

Original language	English
Pages (from-to)	574-580
Number of pages	7
Journal	Annals of Oncology
Volume	15
Issue number	4
DOIs	https://doi.org/10.1093/annonc/mdh131
State	Published - Apr 2004

Keywords

Gastric carcinoma
Prognostic factor
Smad4
Smad7
Transforming growth factor-β

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdh131

Cite this

@article{798174aad0124ac49f0569f71b4767ae,

title = "Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas",

abstract = "Background: Transforming growth factor-β (TGF-β) modulates the growth and function of many cells, including those with malignant transformation. Smad proteins have been identified as major components in the intracellular signaling of TGF-β family members. Patients and methods: To clarify the correlations between clinicopathologic profiles and the patient's survival, the expression of common mediator Smad (Smad4) and inhibitory Smad (Smad7) were evaluated immunohistochemically in 304 consecutive gastric carcinomas using the tissue array method. Results: Positive Smad4 expression was observed in 266 (87.5%) tumors and positive Smad7 expression in 98 (32.2%) tumors. The prognosis of patients with a Smad4-positive tumor was significantly better than that of the patients with a negative tumor. The survival rate was significantly higher in patients with negative Smad7 expression than those with positive Smad7 expression. In subgroup analysis according to TNM (tumour-node-metastasis) stage, both Smad4 and Smad7 showed most significant prognostic differences in stage I gastric cancer patients. Multivariate analysis indicated that tumor size, depth of invasion, lymph node metastasis and Smad7 expression were independent prognostic factors. Conclusion: Enhanced expression of the TGF-β signaling inhibitor Smad7 may present one of the novel mechanisms of TGF-β resistance in human gastric carcinomas.",

keywords = "Gastric carcinoma, Prognostic factor, Smad4, Smad7, Transforming growth factor-β",

author = "Kim, {Y. H.} and Lee, {H. S.} and Lee, {H. J.} and K. Hur and Kim, {W. H.} and Bang, {Y. J.} and Kim, {S. J.} and Lee, {K. U.} and Choe, {K. J.} and Yang, {H. K.}",

year = "2004",

month = apr,

doi = "10.1093/annonc/mdh131",

language = "English",

volume = "15",

pages = "574--580",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas

AU - Kim, Y. H.

AU - Lee, H. S.

AU - Lee, H. J.

AU - Hur, K.

AU - Kim, W. H.

AU - Bang, Y. J.

AU - Kim, S. J.

AU - Lee, K. U.

AU - Choe, K. J.

AU - Yang, H. K.

PY - 2004/4

Y1 - 2004/4

N2 - Background: Transforming growth factor-β (TGF-β) modulates the growth and function of many cells, including those with malignant transformation. Smad proteins have been identified as major components in the intracellular signaling of TGF-β family members. Patients and methods: To clarify the correlations between clinicopathologic profiles and the patient's survival, the expression of common mediator Smad (Smad4) and inhibitory Smad (Smad7) were evaluated immunohistochemically in 304 consecutive gastric carcinomas using the tissue array method. Results: Positive Smad4 expression was observed in 266 (87.5%) tumors and positive Smad7 expression in 98 (32.2%) tumors. The prognosis of patients with a Smad4-positive tumor was significantly better than that of the patients with a negative tumor. The survival rate was significantly higher in patients with negative Smad7 expression than those with positive Smad7 expression. In subgroup analysis according to TNM (tumour-node-metastasis) stage, both Smad4 and Smad7 showed most significant prognostic differences in stage I gastric cancer patients. Multivariate analysis indicated that tumor size, depth of invasion, lymph node metastasis and Smad7 expression were independent prognostic factors. Conclusion: Enhanced expression of the TGF-β signaling inhibitor Smad7 may present one of the novel mechanisms of TGF-β resistance in human gastric carcinomas.

AB - Background: Transforming growth factor-β (TGF-β) modulates the growth and function of many cells, including those with malignant transformation. Smad proteins have been identified as major components in the intracellular signaling of TGF-β family members. Patients and methods: To clarify the correlations between clinicopathologic profiles and the patient's survival, the expression of common mediator Smad (Smad4) and inhibitory Smad (Smad7) were evaluated immunohistochemically in 304 consecutive gastric carcinomas using the tissue array method. Results: Positive Smad4 expression was observed in 266 (87.5%) tumors and positive Smad7 expression in 98 (32.2%) tumors. The prognosis of patients with a Smad4-positive tumor was significantly better than that of the patients with a negative tumor. The survival rate was significantly higher in patients with negative Smad7 expression than those with positive Smad7 expression. In subgroup analysis according to TNM (tumour-node-metastasis) stage, both Smad4 and Smad7 showed most significant prognostic differences in stage I gastric cancer patients. Multivariate analysis indicated that tumor size, depth of invasion, lymph node metastasis and Smad7 expression were independent prognostic factors. Conclusion: Enhanced expression of the TGF-β signaling inhibitor Smad7 may present one of the novel mechanisms of TGF-β resistance in human gastric carcinomas.

KW - Gastric carcinoma

KW - Prognostic factor

KW - Smad4

KW - Smad7

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=2342434705&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh131

DO - 10.1093/annonc/mdh131

M3 - Article

C2 - 15033661

AN - SCOPUS:2342434705

SN - 0923-7534

VL - 15

SP - 574

EP - 580

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -

Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this